Regorafenib (BAY 73-4506)

Catalog No.S1178 Synonyms: Fluoro-Sorafenib

Regorafenib (BAY 73-4506) Chemical Structure

Molecular Weight(MW): 482.82

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.
Targets
RET [1]
(Cell-free assay)
Raf-1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
1.5 nM 2.5 nM 4.2 nM 7 nM 13 nM
In vitro

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. [1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). [2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B MnvRRZBweHSxc3nzJGF{e2G7 M4nLbFHjiJN3wrFOwG0> MV[0PEBp M2CxdolvcGmkaYTzJINmdGxiZ4Lve5Rp NV21PVB7OjZ|Mkm2NFg>
PLC/PRF/5  NF[0NZZCeG:ydH;zbZMhSXO|YYm= M4rhWVHjiJN3wrFOwG0> M4iyOlQ5KGh? M3HobIlvcGmkaYTzJINmdGxiZ4Lve5Rp MWWyOlMzQTZyOB?=
HepG2  NYTMfHBNSXCxcITvd4l{KEG|c3H5 NIe1V4gy6oDVNdMg{txO MXW0PEBp M4TSTIlvcGmkaYTzJINmdGxiZ4Lve5Rp NUjZVGh3OjZ|Mkm2NFg>
HEK293 Mn;iSpVv[3Srb36gRZN{[Xl? NULRUXB5OC534pEJ{txO MYGyM|QwPiCq MYLy[YR2[2W|IFfSVFc5KGW6cILld5Nqd25? M3zufFI2QDV6MEOy
GEO MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\FNE4xOS1{MDFOwG0> NGjBSG86PiCq NEn5[IpFVVOR MUnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{THWVI2QDN6M{mx
SW48 NYTUW4k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnvOlRTOC5yMT2yNEDPxE1? MnzXPVYhcA>? NUnnSllCTE2VTx?= NGHvZYxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXm4bVg{OjV6M{izPVE>
HT29 NIPDcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmwMlAyNTJyIN88US=> NG\1fYM6PiCq NEKyRY9FVVOR NViwRnY2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1;weVI2QDN6M{mx
SW480 Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi5XVcxNjBzLUKwJO69VQ>? MUe5OkBp MWXEUXNQ NF3MUnRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIXNUZozPTh|OEO5NS=>
SW620 NEXDbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DLbFAvODFvMkCg{txO NEfaWlQ6PiCq M33MTmROW09? M33LfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MU[yOVg{QDN7MR?=
HCT116 NV;EXWVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDURpJFOC5yMT2yNEDPxE1? MYG5OkBp NYHlcm1DTE2VTx?= NIe1dmxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1LSSFI2QDN6M{mx
LOVO MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHwNE4xOS1{MDFOwG0> MX65OkBp M4jrNGROW09? MoXKbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NXfBOJNUOjV6M{izPVE>
HCT150 MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjrVXlPOC5yMT2yNEDPxE1? MlrJPVYhcA>? M1zxdmROW09? NV36eHNzcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MUmyOVg{QDN7MR?=
SW48-CR NVnld2Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWWwMlAyNTJyIN88US=> MnHFPVYhcA>? M1TrZmROW09? MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M4XpeFI2QDN6M{mx
GEO-CR NHrPdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHQeFJVOC5yMT2yNEDPxE1? M3PoXlk3KGh? MWTEUXNQ NIqxNVhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NF7meY0zPTh|OEO5NS=>
KB-31 M2HQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTVwNdMxNE4{KG6P MlnQNlU4PTN|NkG=
KB-G2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zoUWlEPTB;OT6xxtExNjFibl2= MUKyOVc2OzN4MR?=
LLC-PK1 NHnYTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXNcGJKSzVyPUSyMlDDuTNwMjDuUS=> M3jtdlI2PzV|M{[x
LLC-PK1/MRP2 NXPpbZRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTKTWM2OD16Mj60xtEzNjdibl2= Ml75NlU4PTN|NkG=
HEK293 M{LX[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFzLkFCtVEvOiCwTR?= M1POblI2PzV|M{[x
HEK293/OATP1B1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHaNpdPUUN3ME22MlLDuTBwMzDuUS=> MlW2NlU4PTN|NkG=
HROC18 NIGye25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTYTWM2OD1zLkOg{txO MnLQNlU{ODl7MUS=
HROC24 M2X1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTRwNjFOwG0> NInIR3kzPTNyOUmxOC=>
HROC43 NXHFPXFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonxTWM2OD13LkOg{txO MmHMNlU{ODl7MUS=
HROC46 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1y4SWlEPTB;Mj60JO69VQ>? NYrsV4o2OjV|MEm5NVQ>
RJ345 M1jNRmZ2dmO2aX;uJGF{e2G7 MkTDNE42NzVizszN MV2yOEBp NEWxTXNFVVOR M2SxOolvcGmkaYTzJJRp\SClZXzsJI1q\3KjdHnvci=> MWqyOVI2Ozl7NB?=
RJ348 NIOzb|dHfW6ldHnvckBCe3OjeR?= NXrvfWo3OC53L{Wg{txO M2fzNVI1KGh? NYHQN5dKTE2VTx?= NYG4d|JucW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v M2\IUFI2OjV|OUm0
MCF-7 M{nUc2Z2dmO2aX;uJGF{e2G7 MoKwNE42NzVizszN M4fOWFI1KGh? MX7EUXNQ MXjpcohq[mm2czD0bIUh[2WubDDtbYdz[XSrb36= NFXEPJozPTJ3M{m5OC=>
MDA-MB-231 NFPyV3NHfW6ldHnvckBCe3OjeR?= NIT3OJExNjVxNTFOwG0> NHnXdnMzPCCq NVrGc3JDTE2VTx?= NYnvV3VmcW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v NUTpfW5iOjV{NUO5PVQ>
HT15 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULhRXBlOS1{MDFOwG0> MorGOFghcA>? MXXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MnrMNlUxPzFyMUi=
DLD1 M4\kR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKxMVIxKM7:TR?= M4[4W|Q5KGh? NHzXSFNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NYDWUHVPOjVyN{GwNVg>
HT-29 NEPzfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M325b|EuOjBizszN NXnCUnVvPDhiaB?= NF3IV49qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUeyOVA4OTBzOB?=
Hct-116 M{jSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fBUVEuOjBizszN M4n2U|Q5KGh? NWq4XlhEcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mn;iNlUxPzFyMUi=
HT15 MoezRZBweHSxc3nzJGF{e2G7 MYKxMVExKM7:TR?= NXniepdzPDhiaB?= M4LIWolv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NIG3UHIzPTB5MUCxPC=>
DLD1 NV3nfXdPSXCxcITvd4l{KEG|c3H5 NH;YcpIyNTFyIN88US=> M3W3SFQ5KGh? NVjNT5RrcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NGfiUFgzPTB5MUCxPC=>
HT-29 MmjxRZBweHSxc3nzJGF{e2G7 MYixMVExKM7:TR?= MnLDOFghcA>? NUPUU|JwcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnjsNlUxPzFyMUi=
Hct-116 MkLORZBweHSxc3nzJGF{e2G7 NIXpUZoyNTFyIN88US=> NGXSPJg1QCCq NHTNPIlqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYWyOVA4OTBzOB?=
GBM5 MkPhRZBweHSxc3nzJGF{e2G7 M4L0SlAvPeLCk{GuNQKBkc7:TR?= NGPifYIzPCCq Mk\mSG1UVw>? NYS0NmdNcW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp M2jucFI1QTFzMkG1
GBM6 MY\BdI9xfG:|aYOgRZN{[Xl? M2\FW|AvPeLCk{GuNQKBkc7:TR?= M1\IUVI1KGh? NVTONIVGTE2VTx?= NXj6VZZCcW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp MUOyOFkyOTJzNR?=
GBM12 MkHjRZBweHSxc3nzJGF{e2G7 NXTLOm9NOC534pETNU4x6oDLzszN MVyyOEBp MnrmSG1UVw>? M1rpR4lvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> NYnvVZB2OjR7MUGyNVU>
GBM14  MmjFRZBweHSxc3nzJGF{e2G7 MkHoNE426oDVMT6w5qCK|ryP MWGyOEBp MUPEUXNQ NYXERYxwcW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp MmLlNlQ6OTF{MUW=
Hep3B NGrVPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PtdVHjiJN{LkZCpO69VQ>? MkHuNlQwPDhxN{KgbC=> NFPsc2dqdmirYnn0d{Bk\WyuIHfyc5d1cA>? Mni0NlQ5QDV6OUC=
PLC/PRF/5  NW\JfXBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHQXGUy6oDVMj61xsDPxE1? MVOyOE81QC95MjDo MVTpcohq[mm2czDj[YxtKGe{b4f0bC=> MnnSNlQ5QDV6OUC=
HepG2  NXi4WXlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j2fVHjiJN{LkZCpO69VQ>? NETMPWYzPC92OD:3NkBp NGHyUFRqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NFy4foYzPDh6NUi5NC=>
HCT116  NXjMR5BNTnWwY4Tpc44hSXO|YYm= MmHuNVAwOjBxNECg{txO MXuyOEBp NIXmb|FqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgcXJPSSCneIDy[ZN{cW:wIHnuJIEh\G:|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MWKyOFc3OzZzMR?=
Lim2405 NGrMVZVHfW6ldHnvckBCe3OjeR?= MlTzOFAh|ryP NXWwWmZyOjRiaB?= NHfseVNqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NWL1O5Z3OjR5NkO2NVE>
LoVo MYnGeY5kfGmxbjDBd5NigQ>? NVzCW494PDBizszN M3\PfFI1KGh? NFHSOXNqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NHntUIwzPDd4M{[xNS=>
Lim1215 NXjMeFBKTnWwY4Tpc44hSXO|YYm= MY[0NEDPxE1? MXKyOEBp NFzkTZlqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NIjCfo4zPDd4M{[xNS=>
SW48 MXfGeY5kfGmxbjDBd5NigQ>? MlrrOFAh|ryP M2q1d|I1KGh? M2K3Tolv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? M2\qelI1PzZ|NkGx
RKO  M{nVSWZ2dmO2aX;uJGF{e2G7 M2jlfVQxKM7:TR?= NF[1NXIzPCCq MWXpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> NH7vfWszPDd4M{[xNS=>
SW837 M{nR[mZ2dmO2aX;uJGF{e2G7 NFnFbpY1OCEQvF2= M3jCNVI1KGh? M1ziS4lv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? NYrNWJh7OjR5NkO2NVE>
SW1463 MYTGeY5kfGmxbjDBd5NigQ>? NWrpVYdKPDBizszN NXPJd40{OjRiaB?= NF;jdXhqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MVOyOFc3OzZzMR?=
SW480 MlrtSpVv[3Srb36gRZN{[Xl? Mn34OFAh|ryP NEK2eYMzPCCq MWDpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> MXSyOFc3OzZzMR?=
Vaco432 NXHUe25bTnWwY4Tpc44hSXO|YYm= NUnT[YpFPDBizszN NFna[HAzPCCq M1zZ[olv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? NWXr[GtXOjR5NkO2NVE>
Vaco400 MU\GeY5kfGmxbjDBd5NigQ>? NV7qO5l3PDBizszN NV7pRZQ5OjRiaB?= NHLFd3RqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MX[yOFc3OzZzMR?=
DLD1 MYnGeY5kfGmxbjDBd5NigQ>? M3jrTVQxKM7:TR?= MUeyOEBp MlrobY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ NUTEe|h[OjR5NkO2NVE>
HT29  NVzjOYJWTnWwY4Tpc44hSXO|YYm= MlruOFAh|ryP M1TNXlI1KGh? MX3pcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> NGrGRmMzPDd4M{[xNS=>
PLC/PRF/5  MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfGN411OeLCk{ZCuW0> MYGyOE81QC95MjDo NIPYVWZqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NH\sXG4zOzF4OUG0PC=>
HepG2 NWnidZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MormNgKBmzYEtV2= NYjxfGJ6OjRxNEivO|IhcA>? MYXpcohq[mm2czDj[YxtKGe{b4f0bC=> M1uxeVI{OTZ7MUS4
Hep3B  M2\3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;DelEy6oDVNdM1US=> NUfmbnFJOjRxNEivO|IhcA>? M17YOolvcGmkaYTzJINmdGxiZ4Lve5Rp NUXFPZI3OjNzNkmxOFg>

... Click to View More Cell Line Experimental Data

In vivo Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. [1]

Protocol

Kinase Assay:[1]
+ Expand

Kinase assays:

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
Cell Research:[1]
+ Expand
  • Cell lines: GIST 882 and TT cells
  • Concentrations: 5 nM-10 μM
  • Incubation Time: 96 hours
  • Method: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O
  • Formulation: PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua)
  • Dosages: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 97 mg/mL (200.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL (suspension)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 482.82
Formula

C21H15ClF4N4O3

CAS No. 755037-03-7
Storage powder
Synonyms Fluoro-Sorafenib

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02795156 Recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer September 28, 2016 Phase 2
NCT03042689 Not yet recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Bayer January 2017 Phase 1
NCT02910843 Not yet recruiting Rectal Cancer Swiss Group for Clinical Cancer Research December 2016 Phase 1
NCT02940223 Not yet recruiting Malignant Neoplasms of Independent (Primary) Multiple Sites|Metastatic Colorectal Cancer M.D. Anderson Cancer Center|Bayer December 2016 Phase 2
NCT02955940 Enrolling by invitation Pancreatic Cancer|Colorectal Cancer|Breastcancer|Lung Cancer Non-Small Cell Incyte Corporation November 2016 Phase 2
NCT02889328 Recruiting Gastrointestinal Stromal Tumors (GISTs) Asan Medical Center September 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) supplier | purchase Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) cost | Regorafenib (BAY 73-4506) manufacturer | order Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID